A retrospective cohort study shows SBRT provides excellent local control in early-stage lung cancer, suggesting safe implementation with careful planning.
Key Points
The study aims to assess the safety and efficacy of SBRT for centrally and ultra-centrally located early-stage NSCLC using real-world data.
Retrospective cohort study with patients from two radiotherapy centers
Patients treated with SBRT following NRG Oncology/RTOG 0813 protocol
Endpoints focused on treatment-related toxicity, local progression-free survival, and overall survival
Survival analysis conducted using the Kaplan–Meier method
78 patients included: 52 with centrally located tumors, 26 with ultra-centrally located tumors
Overall objective response rate was 92.3%
4-year local progression-free survival was 97.4% (100% for central and 91.6% for ultra-central tumors)
4-year overall survival was 98.7%, with no treatment-related deaths
Minimal treatment-related toxicity: only one patient (1.3%) experienced grade ≥2 events